AbbVie Inc (ABBV) Position Cut by Aperio Group LLC
Aperio Group LLC lessened its holdings in shares of AbbVie Inc (NYSE:ABBV) by 0.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,022,172 shares of the company’s stock after selling 905 shares during the quarter. Aperio Group LLC owned about 0.07% of AbbVie worth $96,677,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Mainstay Capital Management LLC ADV grew its holdings in AbbVie by 6,123.5% during the 2nd quarter. Mainstay Capital Management LLC ADV now owns 12,447 shares of the company’s stock valued at $143,000 after buying an additional 12,247 shares in the last quarter. First Mercantile Trust Co. purchased a new position in shares of AbbVie in the 2nd quarter worth approximately $150,000. MUFG Securities EMEA plc purchased a new position in shares of AbbVie in the 2nd quarter worth approximately $157,000. Rainier Group Investment Advisory LLC purchased a new position in shares of AbbVie in the 1st quarter worth approximately $161,000. Finally, Kiley Juergens Wealth Management LLC boosted its holdings in shares of AbbVie by 69.3% in the 3rd quarter. Kiley Juergens Wealth Management LLC now owns 1,761 shares of the company’s stock worth $166,000 after purchasing an additional 721 shares during the period. 69.26% of the stock is currently owned by institutional investors.
ABBV opened at $89.48 on Tuesday. AbbVie Inc has a 52-week low of $77.50 and a 52-week high of $125.86. The company has a debt-to-equity ratio of 8.70, a current ratio of 1.20 and a quick ratio of 1.08. The firm has a market cap of $137.68 billion, a P/E ratio of 15.98, a price-to-earnings-growth ratio of 0.85 and a beta of 1.62.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 15th. Investors of record on Tuesday, January 15th will be issued a dividend of $1.07 per share. The ex-dividend date is Monday, January 14th. This represents a $4.28 dividend on an annualized basis and a yield of 4.78%. This is a boost from AbbVie’s previous quarterly dividend of $0.96. AbbVie’s payout ratio is presently 68.57%.
A number of equities analysts have recently commented on the company. Credit Suisse Group set a $85.00 target price on AbbVie and gave the stock a “sell” rating in a report on Saturday, October 20th. Bank of America dropped their target price on AbbVie from $112.00 to $105.00 and set a “buy” rating for the company in a report on Monday, July 30th. BMO Capital Markets dropped their target price on AbbVie from $78.00 to $71.00 and set an “underperform” rating for the company in a report on Monday, November 5th. Cowen set a $110.00 target price on AbbVie and gave the stock a “buy” rating in a report on Friday, July 27th. Finally, SunTrust Banks dropped their target price on AbbVie from $157.00 to $135.00 and set a “buy” rating for the company in a report on Monday, October 22nd. Four research analysts have rated the stock with a sell rating, seven have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $103.68.
TRADEMARK VIOLATION WARNING: “AbbVie Inc (ABBV) Position Cut by Aperio Group LLC” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/11/20/abbvie-inc-abbv-position-cut-by-aperio-group-llc.html.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection for autoimmune diseases; IMBRUVICA, an oral therapy for patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C.
Read More: Return on Investment (ROI)
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.